Mavenir acquires ip.access to expand OpenRAN radio portfolio for CSPs and Enterprise Private Networks
28.9.2020 15:00:00 EEST | Business Wire | Press release
Mavenir, a leading provider of end-to-end cloud-native Network Software Provider for Communications Service Providers (CSPs) announces today that it has acquired ip.access Ltd, a leading 2G, 3G, 4G and 5G-ready small cell solutions provider. This acquisition extends Mavenir’s leadership in OpenRAN radio on three fronts:
- Communication Service Providers: Adding 2G and 3G capabilities to the OpenRAN portfolio
- Enterprise: Adding a full suite of enterprise radio solutions for Mavenir’s Private Network offerings, including OnGo/CBRS certified solutions
- Nontraditional Networks: Leveraging market leading software defined vRAN solutions for Aviation, Maritime, Rural and Remote networks with next generation solutions in the air, on land and at sea.
“Operators are looking to transform their 2G/3G networks as they migrate to 4G and 5G,” said Pardeep Kohli, President and CEO, Mavenir. “We expect to provide a seamless, multi radio access technology single RAN offering for those operators that allows them to have the benefits of advanced radio solutions across all layers.”
“ip.access brings a strong foothold in 2G, 3G and 4G as well as in the enterprise space that we believe augments Mavenir’s market leadership,” said Aniruddho Basu, SVP and GM Emerging Business, Mavenir. “Combining our assets enhances our end-to-end network proposition, provides a “Multi-G” single RAN evolution path for carriers, and creates a market leading proposition for the private networks enterprise market.”
“Many subscribers in many networks and geographies need GSM and 3G service with LTE even as 5G is introduced. Mavenir’s OpenRAN and Enterprise solutions combined with ip.access’ multi-Radio Access Technologies positions the combined company perfectly for that future,” said Richard Staveley, ip.access CEO.
Nick Johnson, Founder and CTO of ip.access added, “CBRS/OnGo in the US and shared spectrum initiatives in Europe are but a few of the potential opportunities. It’s not just consumer services anymore, but industrial private networks, professional closed group networks for financial, healthcare, leisure and hospitality, among many others. We look forward to applying our long experience in private networks to complement Mavenir’s existing portfolio in serving this hugely expanded customer base.”
ip.access will operate as a business unit within Mavenir’s Emerging Business group and is expected to develop strong synergies with Mavenir’s OpenRAN, Cloud Core, Edge, and Analytics suites for compelling end-to-end network propositions for both the CSP and Enterprise/Industry segments. ip.access brings its proven track record with more than 50 live networks deployed globally with CSPs, and hundreds of private networks for industry, critical infrastructures, data monetization, security and surveillance.
About ip.access:
ip.access has been developing carrier grade solutions since 2002 and is a market leader for Small Cell and Presence Sensor solutions. Serving Communication Service Providers, Private Enterprises and other special Applications markets globally with portfolio of small cells solutions. With a strong track record of working with trusted partners on integrated solutions and services, ip.access unlocks spectrum value for customers globally. www.ipaccess.com
About Mavenir:
Mavenir is a leading end-to-end, cloud-native Network Software and Solutions/Systems Integration Provider, focused on accelerating software network transformation for Communications Service Providers (CSPs). Mavenir offers a comprehensive end-to-end product portfolio across every layer of the network infrastructure stack. From 5G application/service layers to packet core and RAN, Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users. Leveraging innovations in IMS (VoLTE, VoWiFi, Advanced Messaging (RCS)), Private Networks as well as vEPC, 5G Core and OpenRAN vRAN, Mavenir accelerates network transformation for more than 250+ CSP customers in over 120 countries, which serve over 50% of the world’s subscribers.
Mavenir embraces disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve web-scale economics, Mavenir offers solutions to help CSPs with cost reduction, revenue generation, and revenue protection. www.mavenir.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200928005183/en/
Contact information
Mavenir:
Maryvonne Tubb/Denise Hogberg
PR@mavenir.com
ip.access:
Emmanuela Spiteri
emmanuela.spiteri@ipaccess.com
GlobalResults PR
Kevin Taylor
Mavenir@globalresultspr.com
MatterNowPR
Loren Guertin
mavenir@matternow.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom